A Look At Viking Therapeutics (VKTX) Valuation As VK2735 Phase 3 Enrollment Reaches Completion [Yahoo! Finance]
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Yahoo! Finance
Viking Therapeutics (VKTX) shares are back in focus after the company completed enrollment in VANQUISH-2, its Phase 3 trial of obesity and type 2 diabetes drug candidate VK2735. See our latest analysis for Viking Therapeutics. The latest VANQUISH-2 enrollment update comes as Viking Therapeutics trades at US$32.52, with a 1-year total shareholder return of 26.78% and a 5-year total shareholder return of about 4x. Recent 90-day share price returns suggest momentum has cooled after a strong multi year run. If you are tracking how obesity and metabolic treatments are reshaping opportunities in healthcare, it can be useful to see what else is moving in related areas through 34 healthcare AI stocks With Viking now valued at about US$3.96b and the share price well below published analyst targets, the key question is whether this reflects an undervalued obesity contender or if markets are already pricing in future growth. Most Popular Narrative: 65% Undervalued Viking Therapeutic
Show less
Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- Viking Therapeutics (VKTX) Stock Has Failed To Impress Since Jim Cramer Expressed Caution [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics (VKTX) is now covered by Wolfe Research. They set a "peer perform" rating on the stock.MarketBeat
- Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735PR Newswire
- Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today [Yahoo! Finance]Yahoo! Finance
VKTX
Earnings
- 2/11/26 - Miss
VKTX
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/10/26 - Form 4
- 2/11/26 - Form 10-K
- VKTX's page on the SEC website